CONCORDBIO.BOCONCORDBIO.BOBSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +1.42% | +34.77% | -5.47% | -20.35% | +13.74% |
| Gross Profit Growth | -14.62% | +135.52% | -22.74% | -15.32% | -28.61% |
| EBITDA Growth | -7.52% | +38.52% | -29.42% | -23.77% | +1.36% |
| Operating Income Growth | -19.81% | +263.60% | -32.63% | -64.99% | -38.63% |
| Net Income Growth | -2.13% | +47.75% | -26.07% | -34.13% | -15.07% |
| EPS Growth | -2.02% | +47.80% | -26.14% | -34.10% | -15.15% |
| EPS Diluted Growth | -2.02% | +47.80% | -26.14% | -34.10% | -15.15% |
| Weighted Average Shares Growth | -0.11% | -0.03% | +0.10% | -0.05% | +0.04% |
| Weighted Average Shares Diluted Growth | -0.11% | -0.03% | +0.10% | -0.05% | +0.04% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +41.35% | +0.00% | +15.20% | +0.00% |
| Inventory Growth | +0.00% | +15.25% | +0.00% | +10.32% | +0.00% |
| Asset Growth | +0.00% | +19.61% | +0.00% | +14.67% | +0.00% |
| Book Value per Share Growth | +17.56% | +18.78% | +18.62% | +14.97% | +0.00% |
| Debt Growth | +0.00% | -49.40% | +0.00% | -53.07% | +0.00% |
| R&D Expense Growth | +0.00% | +19.81% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | +12.94% | +14.76% | +19.69% | -100.00% | +9.22% |